OncoCyte Net Profit Margin 2014-2024 | OCX
OncoCyte net profit margin from 2014 to 2024. Net profit margin can be defined as net Income as a portion of total sales revenue.
| OncoCyte Net Profit Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Net Income | Net Margin |
| 2024-12-31 | $0.00B | $-0.06B | -6100.00% |
| 2024-09-30 | $0.00B | $-0.04B | 0.00% |
| 2024-06-30 | $0.00B | $-0.04B | 0.00% |
| 2024-03-31 | $0.00B | $-0.04B | 0.00% |
| 2023-12-31 | $0.00B | $-0.03B | 0.00% |
| 2023-09-30 | $0.00B | $-0.06B | 0.00% |
| 2023-06-30 | $0.00B | $-0.06B | 0.00% |
| 2023-03-31 | $0.00B | $-0.06B | 0.00% |
| 2022-12-31 | $0.00B | $-0.07B | 0.00% |
| 2022-09-30 | $0.00B | $-0.06B | 3200.00% |
| 2022-06-30 | $0.00B | $-0.07B | 6800.00% |
| 2022-03-31 | $0.00B | $-0.07B | -7000.00% |
| 2021-12-31 | $0.00B | $-0.06B | -3200.00% |
| 2021-09-30 | $0.01B | $-0.03B | -680.00% |
| 2021-06-30 | $0.01B | $-0.03B | -540.00% |
| 2021-03-31 | $0.00B | $-0.03B | -866.67% |
| 2020-12-31 | $0.00B | $-0.03B | -1500.00% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical Services | $0.087B | $0.002B |
| OncoCyte Corporation is primarily focused on the development of novel, non-invasive blood and urine diagnostic tests for detection of cancer. OncoCyte Corporation is based in Alameda, California. | |||